Home > Insider Trading > Filing (0001818382-24-000100)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818382	Humacyte Inc.	HUMA	Biological Products, (No Disgnostic Substances) (2836)	851763759

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1878020	W Brady Dougan	2525 East North Carolina Highway 54 Durham NC 27713		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-06-11	282,000	$7.09	4,907,288	No	4	S	Indirect	By Ayabudge LLC
Common Stock	Disposition	2024-06-11	76,630	$7.02	4,830,658	No	4	S	Indirect	By Ayabudge LLC
Common Stock	Disposition	2024-06-12	271,518	$7.30	4,559,140	No	4	S	Indirect	By Ayabudge LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Ayabudge LLC
No	4	S	Indirect	By Ayabudge LLC
No	4	S	Indirect	By Ayabudge LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	240,832	Indirect	By spouse
Common Stock	510,161	Direct
Common Stock	1,148,240	Indirect	By The Niklason Living Trust

Footnotes

Shares were sold in a private transaction to a trust controlled by family members of Laura E. Niklason, the Reporting Person's spouse. Said family members do not share the same household as the Reporting Person's spouse.
The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.00 to $7.115. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.545. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.